When regulatory requirements conflict with ethical study design: the case of oral ondansetron.

Markman M

Cleveland Clinic Cancer Center, Ohio.

Cancer Invest. 1994;12(6):654-6. doi: 10.3109/07357909409023050.

Abstract

摘要

相似文献

Cancer Invest. 1994;12(6):654-6. doi: 10.3109/07357909409023050.

Ann Intern Med. 1993 Mar 15;118(6):470-1. doi: 10.7326/0003-4819-118-6-199303150-00013.

J Law Med Ethics. 1996 Fall;24(3):252-9. doi: 10.1111/j.1748-720x.1996.tb01860.x.

Ann Oncol. 1997 Jun;8(6):615-6. doi: 10.1023/a:1017186721738.

Important Adv Oncol. 1994:165-77.

N Engl J Med. 1999 Sep 23;341(13):988-92. doi: 10.1056/NEJM199909233411311.

N Engl J Med. 1999 Aug 12;341(7):531-4. doi: 10.1056/NEJM199908123410713.

Oncology. 1996 Jun;53 Suppl 1:78-85. doi: 10.1159/000227645.

Anticancer Drugs. 1993 Dec;4 Suppl 2:3-7.

J Pediatr Hematol Oncol. 1995 May;17(2):145-50. doi: 10.1097/00043426-199505000-00008.

BMJ. 1998 Sep 26;317(7162):875-80. doi: 10.1136/bmj.317.7162.875.

20分钟写一篇综述，助力文献阅读效率提升50倍。

大模型驱动的PubMed中文搜索引擎

学术文献翻译模型，支持多种主流文档格式。